secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0000950170-25-073988
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health submits first CTA module in Europe for RJVA-001 gene therapy in type 2 diabetes
--------------------------------------------------------------------------------

- Submitted first Clinical Trial Application module in Europe for RJVA-001, a gene therapy for type 2 diabetes.
- Expects to dose first patients and report preliminary data in 2026, pending CTA authorization.
- Phase 1/2 study: open-label, dose escalation; primary endpoints safety/tolerability, secondary HbA1c and fasting glucose.
- Preclinical data (ASGCT 2025) showed safety, dose-dependent potency, adaptive nutrient-responsive secretion with low circulating GLP-1.
- Company targets durable disease remission via one-time therapy, reducing burden of lifelong injectable GLP-1 drugs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025073988/0000950170-25-073988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025073988/guts-20250519.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-073988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer